Abstract:
:Schistosomiasis, a grave and debilitating disease of socioeconomic importance, is increasing in incidence despite concerted efforts to control and contain the disease in all the endemic areas. While a multipronged method of control using health education, sanitation and snail control has been used, chemotherapy and chemoprophylaxis play the most important and crucial role in containing/preventing the transmission of the disease. Schistosomicides such as antimonials were introduced, as early as the 1990s as the drugs of choice and continued to be used until the early 1960s. The antimonials were administered intravenously, and produced severe side effects; the various variables that determined their effects at the site of action made their application difficult and adversely affected their use in large scale chemotherapy. The antimonials were then replaced by hycanthone and lucanthone which were administered intramuscularly. These drugs produced immediate side effects such as hepatotoxicity and gastrointestinal disturbances, and were consequently withdrawn. It was then decided that the alternative was to produce synthetic drugs that could be administered orally. Niridazole, oxamniquine, and metrifonate were introduced as schistosomicidal agents, with drugs like oltipraz and amoscanate still at clinical trial phase. Therapeutic doses of drugs like hycanthone, niridazole and amoscanate have been found to cause many major side effects. A significant advance in the control of schistosomiasis chemotherapy is the introduction of a relatively safe, effective, broad spectrum oral helminthic agent, praziquantel. Studies have also shown that oxamniquine is as effective as praziquantel in eliminating intestinal S. mansoni infection, and metrifonate is as effective as praziquantel in eliminating urinary S. haematobium and S. mansoni infections. Praziquantel has been found to be effective in treating S. haematobium infections compared with metrifonate and more effective in treating S. mansoni infection when compared with oxamniquine. Because the drug is effective even when treating advanced hepatosplenic schistosomiasis, with few side effects, praziquantel is currently the drug of choice for the treatment of any kind of schistosomiasis. The only limitation is the cost which restricts its use in many developing countries. While effective, safe drugs for mass chemotherapy are being developed, the problem of therapeutic failure and drug resistance is being reported from certain developing countries. Under these circumstances, alternative drugs must be resorted to. Mass treatment, a crucial goal in the eventual control of schistosomiasis, awaits a well-tolerated and nontoxic drug that will ultimately prove to be effective where cure is definite. Until such a time, while eradication of the disease is a near impossibility, reducing the intensity of infection can ultimately reduce morbidity and even mortality.(ABSTRACT TRUNCATED AT 400 WORDS)
journal_name
Drugsjournal_title
Drugsauthors
Shekhar KCdoi
10.2165/00003495-199142030-00004subject
Has Abstractpub_date
1991-09-01 00:00:00pages
379-405issue
3eissn
0012-6667issn
1179-1950journal_volume
42pub_type
杂志文章,评审相关文献
DRUGS文献大全abstract::Diabetes mellitus has become the most common single cause of end-stage renal disease in the Western world. Diabetic nephropathy, as most forms of renal disease leading to end-stage renal failure, is frequently complicated by arterial hypertension. In type 1 diabetes mellitus the reported excess in arterial hypertensio...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:
更新日期:2003-01-01 00:00:00
abstract::Porcine-derived lung surfactant (PLS; Curosurf) has shown efficacy in neonatal respiratory distress syndrome. PLS consists of phospholipids, mainly dipalmitoylphosphatidylcholine, the primary surface-active agent of natural lung surfactant, and pulmonary surfactant-associated proteins which facilitate spreading and ad...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199448030-00006
更新日期:1994-09-01 00:00:00
abstract::Rupatadine (Rupafin, Rinialer, Rupax, Alergoliber) is a selective oral histamine H(1)-receptor antagonist that has also been shown to have platelet-activating factor (PAF) antagonist activity in vitro. It is indicated for use in seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR) and chronic idiopathic...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200767030-00008
更新日期:2007-01-01 00:00:00
abstract::Ascletis has developed danoprevir (Ganovo®), an orally-administered hepatitis C virus NS3 protease inhibitor, as a treatment for hepatitis C. Based on positive results in phase II and phase III trials in patients with hepatitis C, danoprevir, in combination with ritonavir, peginterferon alfa and ribavirin was recently...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-018-0960-0
更新日期:2018-08-01 00:00:00
abstract::With its approval more than 15 years ago, subcutaneous etanercept (Enbrel(®)) was the first biological disease-modifying antirheumatic drug (bDMARD) and the first tumour necrosis factor inhibitor to be approved for use in rheumatic diseases. Etanercept remains an important cost-effective treatment option in adult pati...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-014-0258-9
更新日期:2014-08-01 00:00:00
abstract::67 samples of 15 different tissues were obtained from 26 patients who were given an intravenous bolus dose of temocillin approximately 3 to 4 hours prior to surgery. 50 tissue samples were obtained from 19 patients who received 1g temocillin and 17 tissue samples were obtained from 7 patients who received 2g temocilli...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-198500295-00034
更新日期:1985-01-01 00:00:00
abstract::Rapid progress has recently been encountered in pharmacologically treating the unborn baby. This unique area of drug therapy raises new methodological and ethical questions. This article is a systematic review of known modalities of fetal pharmacotherapy, and aims to highlight essential principles, difficulties and co...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200262050-00004
更新日期:2002-01-01 00:00:00
abstract::Lung function can be reduced not only by a non-selective beta-blocker but also by a selective beta1-receptor blocker. If both types of drug are without intrinsic sympathomimetic activity, the effect of the non-selective drug is more pronounced than that of a beta1-receptor selective drug under basal conditions. The ef...
journal_title:Drugs
pub_type: 临床试验,杂志文章
doi:10.2165/00003495-197600111-00035
更新日期:1976-01-01 00:00:00
abstract::An enteral suspension (ES)/intestinal gel formulation of levodopa/carbidopa (hereafter referred to as levodopa/carbidopa ES) [Duodopa® (EU); Duopa™ (USA)] has been developed to overcome the fluctuating plasma levodopa concentrations associated with oral levodopa/carbidopa formulations. In various countries, including ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01201-1
更新日期:2019-10-01 00:00:00
abstract::Cefdinir (Omnicef) is an oral third-generation cephalosporin with good in vitro activity against many pathogens commonly causative in community-acquired infections. The drug provides good coverage against Haemophilus influenzae, Moraxella catarrhalis and penicillin-susceptible Streptococcus pneumoniae, the most common...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200464130-00004
更新日期:2004-01-01 00:00:00
abstract::Avapritinib (AYVAKIT™) is a potent and selective tyrosine kinase inhibitor of platelet-derived growth factor receptor alpha (PDGFRA) and KIT activation loop mutants. It is being developed by Blueprint Medicines for the treatment of gastrointestinal stromal tumours (GIST), solid tumours and systemic mastocytosis. Avapr...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01275-2
更新日期:2020-03-01 00:00:00
abstract::Echinocandins are a new class of antifungal agents with a novel mechanism of action (interference with fungal cell wall synthesis). Caspofungin (Cancidas), Caspofungin MSD) is the first echinocandin to be approved and is administered intravenously. Caspofungin 50 mg/day had similar efficacy to intravenous fluconazole ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200363200-00008
更新日期:2003-01-01 00:00:00
abstract::Voriconazole (VFEND), a synthetic second-generation, broad-spectrum triazole derivative of fluconazole, inhibits the cytochrome P450 (CYP)-dependent enzyme 14-alpha-sterol demethylase, thereby disrupting the cell membrane and halting fungal growth. In the US, intravenous and/or oral voriconazole is recommended in adul...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200767020-00009
更新日期:2007-01-01 00:00:00
abstract::Brodalumab (Lumicef(®)) is a human monoclonal immunoglobulin G antibody that is being developed by Kyowa Hakko Kirin in Japan, where it has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. Brodalumab binds with high affinity to interleukin (IL)-...
journal_title:Drugs
pub_type: 杂志文章
doi:10.1007/s40265-016-0634-8
更新日期:2016-09-01 00:00:00
abstract::Inhaled mometasone furoate (Asmanex) is a synthetic corticosteroid indicated for the first-line maintenance prophylactic therapy of persistent asthma in adults and adolescents. It is formulated for delivery via a breath-actuated dry powder inhaler (DPI) [Twisthaler].Inhaled mometasone furoate delivered by DPI is effec...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666080-00011
更新日期:2006-01-01 00:00:00
abstract::The studies reported here were designed to ascertain whether or not the new beta-lactam antibiotic, temocillin, would produce antibiotic-associated colitis in the hamster. The experiments were controlled with clindamycin and cefoxitin, which are known to induce antibiotic-associated colitis experimentally and clinical...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198500295-00012
更新日期:1985-01-01 00:00:00
abstract::Eluxadoline (Truberzi®) is an orally administered, minimally absorbed agent that acts locally in the gastrointestinal tract as a mixed µ-opioid receptor agonist and δ-opioid receptor antagonist. The randomized, double-blind, placebo-controlled, multinational, phase 3 IBS-3001 and IBS-3002 trials examined the efficacy ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-017-0756-7
更新日期:2017-06-01 00:00:00
abstract::Enalapril provides significant haemodynamic, symptomatic and clinical improvement when added to maintenance therapy with digitalis and diuretics in patients with congestive heart failure [NYHA (New York Heart Association) classes II to IV]. These effects are not attenuated during long term therapy. More significantly,...
journal_title:Drugs
pub_type: 临床试验,杂志文章,评审
doi:10.2165/00003495-198937020-00004
更新日期:1989-02-01 00:00:00
abstract::Vildagliptin (Galvus) is an antihyperglycaemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. Such inhibition prevents the degradation of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This results in improved glycaemic control ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/0003495-200868160-00009
更新日期:2008-01-01 00:00:00
abstract::Airway inflammation is central to the pathophysiology of asthma, with treatment directed towards modification of this inflammation and its consequences. The relationship between cigarette smoking and airway inflammation is also well described, but relatively little data are available on the potential influence of smok...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200565110-00005
更新日期:2005-01-01 00:00:00
abstract::Alirocumab (Praluent®) is a fully human monoclonal antibody developed by Regeneron Pharmaceuticals and Sanofi that has been approved in the US as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolaemia (HeFH) or clinical atherosclerotic car...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-015-0469-8
更新日期:2015-09-01 00:00:00
abstract::Intravenous peramivir (Alpivab™; Rapivab®; Rapiacta®; PeramiFlu®), the most recent globally approved inhibitor of influenza neuraminidase, is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years. This article, written from an EU perspective, reviews the clinical use of ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-018-0981-8
更新日期:2018-09-01 00:00:00
abstract::The pathogenesis of postoperative ileus (PI) is multifactorial, and includes activation of inhibitory reflexes, inflammatory mediators and opioids (endogenous and exogenous). Accordingly, various strategies have been employed to prevent PI. As single-modality treatment, continuous postoperative epidural analgesia incl...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200262180-00004
更新日期:2002-01-01 00:00:00
abstract:OBJECTIVE:The aim of this article is to review data on the efficacy and safety of montelukast in the treatment of children with asthma. METHODOLOGY:Available published literature, including published abstracts, is reviewed. RESULTS:In patients aged 6 to 14 years with asthma (n = 27), montelukast 5mg demonstrated a si...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200059001-00005
更新日期:2000-01-01 00:00:00
abstract::Novo Nordisk has developed a subcutaneous formulation of semaglutide (Ozempic®), a modified human glucagon-like peptide-1 (GLP-1) analogue, for the treatment of type 2 diabetes mellitus. It has been developed using Novo Nordisk's proprietary protein-acylation technology, and is administered using an injection device. ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-018-0871-0
更新日期:2018-02-01 00:00:00
abstract::Aliskiren/hydrochlorothiazide is a single-pill combination of the first in the new class of non-peptide direct renin inhibitors (aliskiren) and a thiazide diuretic (hydrochlorothiazide [HCTZ]) that achieves blood pressure (BP) reductions greater than those seen with either component alone. In double-blind, 8-week clin...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-200969070-00004
更新日期:2009-01-01 00:00:00
abstract::The new therapeutic options available to clinicians treating dyslipidaemia in the last decade have enabled effective treatment for many patients. The development of the HMG-CoA reductase inhibitors (statins) have been a major advance in that they possess multiple pharmacological effects (pleiotropic effects) resulting...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200060010-00005
更新日期:2000-07-01 00:00:00
abstract::Cardiovascular diseases are the leading cause of mortality in industrialized countries. Treatment with statins is effective in primary prevention in patients at high cardiovascular risk. Statins are inhibitors of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase and are classed as lipid-lowering drugs. In 2010, ato...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11632010-000000000-00000
更新日期:2012-04-16 00:00:00
abstract::Acute myocardial infarction (AMI) recognises no boundaries, and the patient's greatest need occurs at the interface between primary care and hospital system. Ideally, the general practitioner, if summoned, should be able to provide resuscitation, analgesia with opiates, and thrombolytic therapy. Thrombolytics should c...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199550040-00004
更新日期:1995-10-01 00:00:00
abstract::Patients frequently come to the emergency department for pain. For decades, ketamine has been used in the emergency department for procedural sedation but is now receiving attention as a potential alternative to opioids because of its unique analgesic effects. Additionally, ketamine's dissociative properties have made...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-018-0904-8
更新日期:2018-05-01 00:00:00